Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

Y0001327

Atorvastatin Calcium Trihydrat

European Pharmacopoeia (EP) Reference Standard

Synonym(e):

Atorvastatin Hemicalciumsalz Sesquihydrat

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C66H68CaF2N4O10 · 3H2O
CAS-Nummer:
344423-98-9
Molekulargewicht:
1209.39
UNSPSC-Code:
41116107
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

atorvastatin

Hersteller/Markenname

EDQM

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

InChI

1S/2C33H35FN2O5.Ca.3H2O/c2*1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40;;;;/h2*3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40);;3*1H2/q;;+2;;;/p-2/t2*26-,27-;;;;/m11..../s1

InChIKey

SHZPNDRIDUBNMH-NIJVSVLQSA-L

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Atorvastatin calcium trihydrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Verpackung

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Sonstige Hinweise

Sales restrictions may apply.

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

1044516

Atorvastatin-Calcium, United States Pharmacopeia (USP) Reference Standard

1044527

Atorvastatin-verwandte Verbindung A, United States Pharmacopeia (USP) Reference Standard

1044538

Atorvastatin-verwandte Verbindung B, United States Pharmacopeia (USP) Reference Standard

1044549

Atorvastatin-verwandte Verbindung C, United States Pharmacopeia (USP) Reference Standard

1044550

Atorvastatin-verwandte Verbindung D, United States Pharmacopeia (USP) Reference Standard

1044571

Atorvastatin-verwandte Verbindung E, United States Pharmacopeia (USP) Reference Standard

Y0001329

Atorvastatin impurity B, European Pharmacopoeia (EP) Reference Standard

Y0001332

Atorvastatin Unreinheit E, European Pharmacopoeia (EP) Reference Standard

1044593

Atorvastatin-verwandte Verbindung I, United States Pharmacopeia (USP) Reference Standard

1044582

Atorvastatin-verwandte Verbindung H, United States Pharmacopeia (USP) Reference Standard

PHR1873

5-(4-Fluorphenyl)-1-{2-[(2R, 4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]-ethyl}-2-isopropyl-N,4-diphenyl-1H-pyrrol-3-carboxamid, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1869

Atorvastatin-verwandte Verbindung B, pharmaceutical secondary standard, certified reference material

PHR1872

Atorvastatin-verwandte Verbindung E, pharmaceutical secondary standard, certified reference material

PHR1874

Atorvastatin-verwandte Verbindung I, pharmaceutical secondary standard, certified reference material

PHR1870

Atorvastatin-verwandte Verbindung C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1871

3-(4-Fluorbenzoyl)-2-(2-methyl-1-oxopropyl)-N,3-diphenyl-oxirancarboxamid, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1868

Atorvastatin Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2421

1,1-Dimethylethyl (4R-cis)-6-Aminoethyl-2,2-dimethyl-1,3-dioxane-4-acetate

Y0002315

Atorvastatin calcium, CRS, European Pharmacopoeia (EP) Reference Standard

Piktogramme

Health hazard
GHS08

Signalwort

Danger

H-Sätze

H351 - H360D

Gefahreneinstufungen

Carc. 2 - Repr. 1B

Lagerklassenschlüssel

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Choose from one of the most recent versions:

Analysenzertifikate (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 3

1 of 3

Atorvastatin-verwandte Verbindung B United States Pharmacopeia (USP) Reference Standard

USP

1044538

Atorvastatin-verwandte Verbindung B

Atorvastatin-verwandte Verbindung A United States Pharmacopeia (USP) Reference Standard

USP

1044527

Atorvastatin-verwandte Verbindung A

Ezetimib United States Pharmacopeia (USP) Reference Standard

USP

1269028

Ezetimib

Hongshi Li et al.
Cardiovascular journal of Africa, 30(5), 268-274 (2019-07-31)
Our previous experiments showed that the transient sodium current (INa) was abnormally increased in early ischaemia and atorvastatin could inhibit INa. The aim of this study was to observe the time-dependent effects of simulated ischaemia on INa and characterise the
Fang Hu et al.
AMB Express, 9(1), 37-37 (2019-03-20)
The aim of the present study was to evaluate the protective effects of combined atorvastatin and amygdalin in a rat model of endometriosis. Tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), matrix metalloproteinase-2 (MMP-2) and MMP-9 levels in the peritoneal fluid were
Masaki Watanabe et al.
Drug metabolism and pharmacokinetics, 30(2), 198-204 (2015-05-21)
Since drug-drug interaction (DDI) can affect organic anion-transporting polypeptide (OATP) and cause clinical events, prediction of such DDI is important in early clinical development. Although statins are useful probes for OATP-mediated DDI, endogenous probes would be more practical for predicting
Alexander Treiber et al.
The Journal of pharmacology and experimental therapeutics, 350(1), 130-143 (2014-04-29)
Treatment of pulmonary arterial hypertension with the endothelin receptor antagonist bosentan has been associated with transient increases in liver transaminases. Mechanistically, bosentan inhibits the bile salt export pump (BSEP) leading to an intrahepatic accumulation of cytotoxic bile salts, which eventually

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.